David Sedlak

Dr. David Sedlak

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Nature Methods
Verified
Journal Article
Closed access
CSCtibor Skuta
Ctibor Skuta
MPMartin Popr
Martin Popr
TMTomas Muller
Tomas Muller
JJJindrich Jindrich
Jindrich Jindrich
MKMichal Kahle
Michal Kahle
PBPetr Bartůněk
Petr Bartůněk

22 November 2016 in Journal of Natural Products
Verified
Journal Article
Closed access
DBDavid Biedermann
David Biedermann
MBMartin Buchta
Martin Buchta
VHVeronika Holečková
Veronika Holečková
DSDavid Sedlak
David Sedlak
Kateřina ValentováKateřina Valentová
Kateřina Valentová
VKVladimír Křen
Vladimír Křen

1 May 2011 in Combinatorial Chemistry & High Throughput Screening
Verified
Journal Article
Open access
PDF file
DSDavid Sedlak
David Sedlak
APAileen Paguio
Aileen Paguio
PBPetr Bartůněk
Petr Bartůněk
Steroid hormone receptors represent a major target in drug discovery. As ligand inducible transcription factors, their activity can be modulated by small lipophilic molecules. Here we describe two panels of potent and selective luciferase reporter cell lines based on cells with low endogenous steroid receptor activity (U2OS). The panels contain reporter cell lines for estrogen receptors α and β, androgen, glucocorticoid, mineralocorticoid, and progesterone receptors. In the first panel, the activation of either synthetic, steroid response elements containing promoter or viral promoter is mediated by full-length steroid receptors. The second panel is based on the expression of the chimeric receptor, which was created by the replacement of the N-terminal part of the molecule by Gal4 DBD and that binds to multiple UAS sites in the reporter promoter. Both panels were extensively characterized by profiling 28 ligands in dose response manner in agonist and antagonist mode. We have analyzed and compared the responses to tested ligands from both panels and concluded that in general both systems generated similar qualitative response in terms of potency, efficacy, partial agonism/antagonism, mixed agonistic/antagonistic profiles and the rank of potencies was well conserved between both panels. However, we have also identified some artifacts introduced by the Gal4/LBD reporter assays in contrast to their full-length receptor reporter counterparts. Keeping in mind the advantages and drawbacks of each reporter format, these cell lines represent powerful and selective tools for profiling large compound libraries (HTS) and for detailed study of mechanisms by which compounds exert their biological effects.

12 July 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GSGabriela Seydlová
Gabriela Seydlová
RPRadek Pohl
Radek Pohl
EZEva Zborníková
Eva Zborníková
MEMarcel Ehn
Marcel Ehn
OŠOndřej Šimák
Ondřej Šimák
DRDominik Rejman
Dominik Rejman

28 June 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
DSDavid Sedlak
David Sedlak
TWTyler A. Wilson
Tyler A. Wilson
WTWerner Tjarks
Werner Tjarks
HRHanna S. Radomska
Hanna S. Radomska
HWHongyan Wang
Hongyan Wang
CCChristopher Coss
Christopher Coss
Selective agonism of the estrogen receptor (ER) subtypes, ERα and ERβ, has historically been difficult to achieve due to the high degree of ligand-binding domain structural similarity. Multiple efforts have focused on the use of classical organic scaffolds to model 17β-estradiol geometry in the design of ERβ selective agonists, with several proceeding to various stages of clinical development. Carborane scaffolds offer many unique advantages including the potential for novel ligand/receptor interactions but remain relatively unexplored. We synthesized a series of para-carborane estrogen receptor agonists revealing an ERβ selective structure–activity relationship. We report ERβ agonists with low nanomolar potency, greater than 200-fold selectivity for ERβ over ERα, limited off-target activity against other nuclear receptors, and only sparse CYP450 inhibition at very high micromolar concentrations. The pharmacological properties of our para-carborane ERβ selective agonists measure favorably against clinically developed ERβ agonists and support further evaluation of carborane-based selective estrogen receptor modulators.

1 May 2016 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
LRLucie Rárová
Lucie Rárová
JSJana Steigerová
Jana Steigerová
MKMiroslav Kvasnica
Miroslav Kvasnica
PBPetr Bartůněk
Petr Bartůněk
KKKateřina Křížová
Kateřina Křížová
MSMiroslav Strnad
Miroslav Strnad